Advertisement
IONS vs MNKD
Which Stock Would AI Choose? Ionis Pharmaceuticals (IONS) vs. MannKind Corporation (MNKD) Stock Comparison
Key Takeaways
- IONS boasts a significantly larger market capitalization of approximately $12 billion compared to MNKD's $800 million, reflecting greater scale and stability.
- Over the past year, IONS has delivered substantial gains, with reports highlighting over 400% appreciation, driven by commercial advancements.
- MNKD reported strong Q4 2025 revenue growth of 46% year-over-year, led by Furoscix sales up 91%, yet shares have declined sharply year-to-date by over 50%.
- Recent market activity shows IONS trading around $73 with higher volatility but positive long-term momentum, while MNKD hovers near $2.70 amid post-earnings pressure.
- Both operate in biotechnology, but IONS focuses on RNA-targeted therapies with partnerships, contrasting MNKD's inhaled drug delivery emphasis.
Introduction
This stock comparison evaluates IONS and MNKD, two biotechnology firms navigating distinct paths in therapeutic innovation. Investors interested in biotech sector exposure, particularly those assessing relative performance amid recent market volatility, may find value here. IONS represents a leader in RNA therapeutics, while MNKD specializes in inhaled delivery systems. By examining recent price behavior, business drivers, and sentiment shifts, this analysis aids traders in understanding trade-offs in growth potential versus risk in the current environment.
IONS Overview and Recent Performance
Ionis Pharmaceuticals (IONS) is a biotechnology pioneer in antisense oligonucleotide technology—short synthetic DNA-like molecules that target RNA to modulate gene expression for treating rare diseases and neurological disorders. The company operates a hybrid model of proprietary development and partnerships with major pharma firms, recently advancing to commercial-stage with FDA approval for Wainua (eplontersen) for transthyretin amyloidosis.
In recent market activity, IONS shares have traded around $73, reflecting a pullback from peaks near $86 but maintaining strong yearly gains amid broader biotech optimism. Sentiment has been buoyed by commercial milestones and pipeline progress, though short-term pressure from sector rotation and earnings anticipation has tempered momentum. Trading volume remains robust, underscoring investor interest in its diversified RNA platform.
MNKD Overview and Recent Performance
MannKind Corporation (MNKD) focuses on innovative inhaled therapeutics via its proprietary Technosphere platform, a dry powder inhalation technology for pulmonary delivery. Key products include Afrezza (inhaled insulin for diabetes) and Furoscix (self-administered furosemide for heart failure), emphasizing patient-centric chronic disease management.
Recent weeks have seen MNKD shares fluctuate near $2.70, down significantly from 52-week highs above $6, influenced by post-earnings selling despite robust Q4 revenue growth. Positive developments like expanding Furoscix adoption have supported fundamentals, but heightened volatility and year-to-date declines reflect market concerns over execution risks and dilution potential in this smaller-cap name.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from over 350 available bots that analyze thousands of tickers across stocks, ETFs, and crypto. Only the most suitable for prevailing market conditions earn a spot among the 25 featured trending bots, each employing unique strategies like AI/ML trend following, signal generation, or double-agent trading, with timeframes from 5 minutes to 55 days. Performance stats impress: annualized returns range from +15% to +168%, win rates 48%-88%, and profit factors up to 4.53, often focusing on sectors like semiconductors, energy, or small caps. These bots offer copy trading with risk controls, appealing to automated strategy seekers. Explore Trending AI Robots for potential edges in dynamic markets.
Head-to-Head Comparison
IONS and MNKD both target biotech innovation but diverge in business models: IONS leverages scalable RNA-targeting for broad pipeline partnerships, reducing single-product risk, while MNKD hinges on niche inhaled delivery with fewer but growing commercial revenues.
Growth drivers contrast sharply—IONS benefits from diverse catalysts like Wainua launches, versus MNKD's reliance on Afrezza/Furoscix uptake amid reimbursement hurdles. Recent momentum favors IONS's steadier uptrend over MNKD's sharp declines, though the latter shows revenue acceleration.
Risk profiles differ: IONS faces clinical trial uncertainties but enjoys pharma collaborations; MNKD contends with higher volatility, cash burn, and competition in diabetes/heart failure. Sector exposure aligns in biotech, yet IONS garners stronger analyst sentiment and institutional backing, positioning it for relative outperformance in risk-averse environments.
Tickeron AI Verdict
Tickeron’s AI analysis leans toward IONS in the current market, citing superior trend consistency, larger scale buffering volatility, and catalysts like commercial launches amid biotech recovery. MNKD offers higher upside potential from revenue ramps but trails in stability and momentum. Probabilistic edge favors IONS for balanced positioning, though monitoring earnings and sector flows remains key.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IONS is a Buy and MNKD is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IONS’s FA Score shows that 0 FA rating(s) are green whileMNKD’s FA Score has 1 green FA rating(s).
- IONS’s FA Score: 0 green, 5 red.
- MNKD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IONS’s TA Score shows that 5 TA indicator(s) are bullish while MNKD’s TA Score has 4 bullish TA indicator(s).
- IONS’s TA Score: 5 bullish, 4 bearish.
- MNKD’s TA Score: 4 bullish, 4 bearish.
Price Growth
IONS (@Biotechnology) experienced а +3.97% price change this week, while MNKD (@Biotechnology) price change was -2.75% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.83%. For the same industry, the average monthly price growth was +1.96%, and the average quarterly price growth was +1945.11%.
Reported Earning Dates
IONS is expected to report earnings on Aug 05, 2026.
MNKD is expected to report earnings on Aug 12, 2026.
Industries' Descriptions
@Biotechnology (+5.83% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| IONS | MNKD | IONS / MNKD | |
| Capitalization | 12.6B | 1.21B | 1,040% |
| EBITDA | -217.15M | 27.6M | -787% |
| Gain YTD | -3.944 | -31.393 | 13% |
| P/E Ratio | N/A | 143.00 | - |
| Revenue | 1.06B | 361M | 293% |
| Total Cash | 1.92B | 134M | 1,432% |
| Total Debt | 2.04B | 331M | 617% |
IONS | MNKD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 40 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 34 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 46 | 41 | |
P/E GROWTH RATING 1..100 | 62 | 5 | |
SEASONALITY SCORE 1..100 | n/a | 34 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MNKD's Valuation (92) in the Biotechnology industry is in the same range as IONS (100). This means that MNKD’s stock grew similarly to IONS’s over the last 12 months.
IONS's Profit vs Risk Rating (34) in the Biotechnology industry is significantly better than the same rating for MNKD (100). This means that IONS’s stock grew significantly faster than MNKD’s over the last 12 months.
IONS's SMR Rating (99) in the Biotechnology industry is in the same range as MNKD (100). This means that IONS’s stock grew similarly to MNKD’s over the last 12 months.
MNKD's Price Growth Rating (41) in the Biotechnology industry is in the same range as IONS (46). This means that MNKD’s stock grew similarly to IONS’s over the last 12 months.
MNKD's P/E Growth Rating (5) in the Biotechnology industry is somewhat better than the same rating for IONS (62). This means that MNKD’s stock grew somewhat faster than IONS’s over the last 12 months.
| IONS | MNKD | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 67% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 70% | 2 days ago 77% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 73% |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 74% | 2 days ago 78% |
| Advances ODDS (%) | 20 days ago 67% | 6 days ago 79% |
| Declines ODDS (%) | 16 days ago 63% | 16 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 72% | 2 days ago 88% |
| Aroon ODDS (%) | N/A | 2 days ago 79% |
Advertisement
MNKD and
Correlation & Price change
A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with IONS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then IONS could also see price increases.
| Ticker / NAME | Correlation To MNKD | 1D Price Change % | ||
|---|---|---|---|---|
| MNKD | 100% | -1.27% | ||
| IONS - MNKD | 47% Loosely correlated | +2.39% | ||
| VCYT - MNKD | 44% Loosely correlated | -0.82% | ||
| CYTK - MNKD | 40% Loosely correlated | +0.51% | ||
| UTHR - MNKD | 37% Loosely correlated | +0.27% | ||
| AMRN - MNKD | 36% Loosely correlated | -1.15% | ||
More | ||||